



Biotech Daily

Thursday September 17, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: IDT UP 6%; ANALYTICA DOWN 14%**
- * **CHINA POLLUTION CARDIO-RESPIRATORY OPPORTUNITY FOR USCOM**
- * **ANU REDUCES BELOW 5% OF BIONOMICS**
- * **WEBINVEST, OTTO BUTTULA TAKE 7% OF ONCOSIL**
- * **SUSAN WHITING DILUTED BELOW 5% OF BIOTECH CAPITAL**
- * **PROTEOMICS RELEASES 1.5m ESCROW SHARES**
- * **OPTISCAN LOSES JULY DIRECTOR GEORGE CAMERON-DOW**
- * **TISSUE THERAPIES LOSES DIRECTOR IAIN ROSS**
- * **BIO-MELBOURNE BRAINSTORMS 'HEALTH HACKATHONS'**

MARKET REPORT

The Australian stock market climbed 0.94 percent on Thursday September 17, 2015 with the ASX200 up 47.9 points to 5,146.8 points. Twenty-one of the Biotech Daily Top 40 stocks were up, nine fell, three traded unchanged and seven were untraded.

IDT was the best for the second day in a row, with chief executive officer Dr Paul MacLeman on an investor roadshow, up two cents or 6.1 percent to 35 cents with 265,808 shares traded.

Medical Developments climbed 5.2 percent; Antisense was up 4.8 percent ; Orthocell and Prima were up more than three percent; Osprey rose 2.2 percent; Admedus, Benitec, Biotron and Clinuvel were up more than one percent; with Resmed up 0.1 percent.

Analytica led the falls, down 0.1 cents or 14.3 percent to 0.6 cents with 520,000 shares traded, followed by Optiscan down 10.6 percent to 4.2 cents with 100,000 shares traded.

Avita lost 9.9 percent; Circadian and Starpharma fell five percent or more; Genetic Technologies fell 4.55 percent; Cellmid, Impedimed, Oncosil and Viralytics were down more than three percent; Nanosonics and Reva shed more than two percent; Acrux, Actinogen, Atcor, Compumedics, Psivida and Sirtex were down more than one percent; with Bionomics, CSL and Mesoblast down by less than one percent.

USCOM

Uscom says that high rates of pollution-induced cardio-respiratory disease in China are an opportunity for its cardiac, vascular and pulmonary monitoring devices.

Uscom said that a study authored by the University of California, Berkeley's Robert Rohde and Robert Muller, based on Chinese air monitoring figures showed that about 1.6 million deaths each year were related to pollution induced cardiac, vascular and pulmonary disease and 55 percent of all deaths were caused by cardio-respiratory disease.

The company said that the study found that pollution was responsible for 17 percent of all the 9.8 million deaths per year equivalent to 4,000 deaths per day with cardio-respiratory causes responsible for 55 percent of all China mortality compared to 42 percent for the United States.

Uscom said that sales of its ultra-sonic cardiac output monitor 1a (Uscom 1a), the Uscom BP+, and the recently acquired Thor Spirometry for monitoring asthma and chronic obstructive pulmonary disease, were set to increase.

Uscom executive chairman Prof Rob Phillips said the data was "astonishing and further emphasize the underlying value of our gold standard technologies and particularly the newly acquired Thor products".

"Our mission has been to develop, manufacture and market practice leading non-invasive cardiovascular and respiratory devices, to detect and monitor major global diseases," Prof Phillips said.

"Uscom has established commercial and educational relationships in China with annual sales growth for 2016 projected to be more than 50 percent," Prof Phillips said.

"Discussions are on-going for distribution of the Thor devices in the Chinese and US markets," Prof Phillips said.

Uscom said that the suite of Thor digital spirometry devices would expand the company's technology into "practice-leading positions in cardiac, vascular and pulmonary applications".

Uscom was unchanged at 13 cents.

BIONOMICS

The Australian National University says it has reduced its holding in Bionomics below the five percent substantial level.

In 2013, the ANU reduced to 21,642,425 shares (5.26%) and today said it had sold 2,000,000 shares for \$1,080,000 or 54 cents a share implying its holding in Bionomics was reduced to 4.7 percent (BD: Aug 13, 2013).

Bionomics retreated half a cent or 0.9 percent to 54 cents with one million shares traded.

ONCOSIL

The Trinity Beach Queensland-based Webinvest says it has increased its holding in Oncosil from 19,133,067 shares (6.33%) to 26,250,000 (7.37%).

In the substantial shareholder notice, Webinvest director Otto Buttula said that 7,116,933 shares were acquired on market on between September 26 2013 and September 16, 2015 for \$677,825 or 9.5 cents a share.

Mr Buttula is also a director of Imugene in which he owns 62,000,000 shares (7.06%) (BD: May 5, Jul 7, 2014).

Oncosil fell half a cent or 3.6 percent to 13.5 cents with 2.5 million shares traded.

BIOTECH CAPITAL

Susan Whiting says she has been diluted below the five percent substantial holding threshold in Biotech Capital by the recent placement.

Ms Whiting, who gave her address as care of the Sydney office of stock brokers Taylor Collison, said that she held 4,300,000 shares which was 5.77 percent of the company when she became substantial in 2013, acquiring the shares for \$122,300 or 2.84 cents a share.

Earlier this month, Biotech Capital raised \$1,028,847 through the issue of 12,860,583 shares at eight cents each to the Auckland Trust Co (BD: Sep 1, 2015).

Biotech Capital was untraded at 11.5 cents.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says that 1,525,938 shares will be released from escrow on September 30, 2015.

Proteomics said that following the release of the shares, it would have 20,500,938 shares available for trading, with a further 30,080,515 shares held in ASX escrow, for a total of 50,581,453 shares on issue.

Proteomics fell one cent or 3.7 percent to 26 cents.

OPTISCAN

Optiscan says that director George Cameron-Dow who was appointed in July has resigned (BD: Jul 21, 2015).

Optiscan said that "given the modest size of the company and its current scale of activity, the directors concluded that a three member board with a non-executive chairman [was] the most cost effective structure".

Optiscan chairman Patrick O'Connor thanked Mr Cameron-Dow for assisting in the recent company review and board transition.

In July, the former executive chairman Angus Holt resigned, following a lengthy and detailed ASX query regarding director's interest disclosures by Mr Holt leading to the appointments of Mr O'Connor and Mr Cameron-Dow (BD: Jul 10, 2015).

Optiscan fell half a cent or 10.6 percent to 4.2 cents.

TISSUE THERAPIES

Tissue Therapies says that non-executive director Iain Ross "has resigned with immediate effect".

Tissue Therapies did not elaborate.

Mr Ross was appointed as a Tissue Therapies director in 2012 (BD: May 25, 2012).

In July, Mr Ross replaced Novogen founder and executive chairman Dr Graham Kelly as Novogen's interim chief executive officer (BD: Jul 22, 2015).

Mr Ross is also a director of Benitec.

Tissue Therapies was untraded at 5.3 cents.

BIO-MELBOURNE NETWORK

The Bio-Melbourne Network says its September 23, 2015 Bio-Briefing will explore the ways "hackathons" can be used to develop innovative solutions to health problems. The Bio-Melbourne Network chief executive officer Dr Krystal Evans told Biotech Daily that the term hackathons derived from the use of "hack" to mean short-cut and hackathons integrated information technology specialists, with engineers, clinicians, entrepreneurs and designers.

"Hackathons match problem owners and problem solvers usually for an information technology and communications-based problem for data handling," Dr Evans said.

"Health hackathons have sprung up around the world, particular in relation to data search and research issues, such as how do we recruit more people into clinical trials, or for patient flows in hospitals, patient compliance with medication and for the social isolation in the elderly," Dr Evans said.

The Network said that the Bio-Briefing, entitled 'Why Hack? Hackathons for healthcare technology' will showcase some of the hackathon events in Melbourne and develop the understanding of the power of these events for driving healthcare innovation in biotechnology and medical technology.

The Network said that health-hacks bring together multi-disciplinary teams over a weekend to "hack" a solution to data-based health problem.

"Digital health is revolutionizing the approach to healthcare," Dr Evans said.

"Right now, digital technology is reshaping the entire research and development pathways for new therapies, devices and treatments," Dr Evans said.

The Network said that the speakers at the workshop will include Ehealth Start-Up's Sam Stewart, Team Eyenemia's Jarrel Seah, Team Girror's Dr Ben Fulcher and Northern Health's chief medical officer Prof Kwang Lim.

The September 23, 2015 Bio-Briefing will be held at the Carlton Connect Initiative, LAB-14, 700 Swanston Street, Carlton, with registration from 3.45pm for the Bio-Briefing from 4pm to 5.10pm followed by a networking session.

To register go to: <http://www.biomelbourne.org/events/view/386>.